In section Market Quotes

Summit Therapeutics Falls 18% After FDA Rejects Ivonescimab Application

Summit Therapeutics shares fell 18% to $11.59 in premarket trading Monday after the FDA declined to approve the company’s ivonescimab application for certain patients with advanced lung cancer. The decision followed the agency’s finding that evidence was insufficient to show the treatment extended patients’ lives.

Summit Therapeutics Falls 18% After FDA Rejects Ivonescimab Application

The company said Sunday it had received a complete response letter from the Food and Drug Administration concerning its biologics license application. The application sought approval for ivonescimab combined with platinum-containing chemotherapy for patients with locally advanced or metastatic non-small cell lung cancer who had already received certain therapies.

Summit shares had lost about a fifth of their value year to date through Friday’s close. Robert Duggan, the company’s co-chief executive, said Summit was “disappointed for patients and their families awaiting additional treatment options in this setting.”

Ivonescimab was initially approved for marketing authorization in China in May 2024. It was developed there by Summit’s partner Akeso. The treatment has not been approved by any regulatory authority in Summit’s license territories, including the U.S. and Europe.

Share:on TelegramXFacebook

Subscribe to our newsletter

Once a week — the best stories from our editors, no ads or push notifications. Delivered Sunday morning.

Comments (0)

Leave a comment

No comments yet. Be the first!